Forte Biosciences Reports Increased Net Loss, Secures Funding, and Advances Clinical Pipeline

summarizeSummary

Forte Biosciences reported a net loss of $69.4 million for 2025 but highlighted successful capital raises, positive clinical data for its lead candidate FB102 in celiac disease, and an extended cash runway of at least 12 months.

check_boxKey Events

• Increased Net Loss for 2025

  The company reported a net loss of $69.4 million for the year ended December 31, 2025, a significant increase from $35.5 million in 2024, primarily due to increased research and development expenses.

• Extended Cash Runway

  As of December 31, 2025, Forte Biosciences had $77.0 million in cash and cash equivalents, which management believes will be sufficient to fund operations for at least 12 months from the filing date.

• Clinical Pipeline Advancement

  Positive Phase 1b data for FB102 in celiac disease was announced in June 2025, leading to the initiation of a Phase 2 study in July 2025, with FDA IND approval for a US arm in November 2025. Phase 1b trials for non-segmental vitiligo and alopecia areata are also underway with topline data expected in 2026.

• Successful Capital Raises

  The company completed a public offering in June 2025, raising $75.0 million, and a private placement in November 2024, raising $53.0 million, significantly bolstering its financial resources.

auto_awesomeAnalysis

This annual report provides a comprehensive update on Forte Biosciences' financial health and clinical development. While the company reported a significant increase in net loss for 2025, it successfully executed substantial capital raises in 2024 and 2025, extending its cash runway to at least 12 months. Positive Phase 1b clinical data for its lead candidate, FB102, in celiac disease, and subsequent progression to Phase 2, along with FDA IND approval, are critical advancements for a clinical-stage biopharmaceutical company. The legal recovery further bolsters its financial position. Investors should monitor the progress of ongoing clinical trials and future financing needs.